Low-frequency Repetitive Nerve Stimulation in Myotonic Dystrophy Type 1

Sponsor
Vrije Universiteit Brussel (Other)
Overall Status
Completed
CT.gov ID
NCT05662150
Collaborator
(none)
9
1
4
9.6
0.9

Study Details

Study Description

Brief Summary

The study design is a prospective cohort study. It aims to evaluate the neuromuscular junction in dystrophic myotonia 1 (DM 1) using low-frequency repetitive nerve stimulation (RNS) on several nerve-muscle pairs of the one side including proximal and distal muscles of upper and lower extremities. First, it will be investigated whether a decrement with 3 Hz stimulation, as described in literature, is reproducible in our patient population. If this is the case, it will be examined whether it is the consequence of a dysfunction of the neuromuscular junction or rather linked to a hypo-excitability of some muscle fibers due to myotonia. For this purpose, additional tests including short exercise test (to observe any decrement resulting from an inexcitability in myotonic muscle fibers) and needle EMG (for mapping myotonic discharges in the muscles tested with repetitive nerve stimulation) will be performed. Single fiber-EMG will not be provided in this study as an abnormal result does not necessarily indicate a dysfunction of the neuromuscular junction but could just as well be due to the muscular dystrophy in the context of DM1. Finally, it will be investigated if there is a correlation between the decrement

with 3 Hz stimulation and clinical signs as fixed muscle weakness (via Medical Research Counsil (MRC) scale, DM-activ scale [30]) and fatigue (via MG-ADL scale).

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Low frequency repetitive stimulation
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
9 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Is Low-frequency Repetitive Nerve Stimulation a Reliable Test to Evaluate the Neuromuscular Junction in Myotonic Dystrophy Type 1
Actual Study Start Date :
Sep 1, 2021
Actual Primary Completion Date :
Jun 11, 2022
Actual Study Completion Date :
Jun 20, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Questionnaires

Patients with DM1 were asked to complete a questionnaire to rate a 25-item activity scale (DM1-Activ) and the Myasthenia Gravis Activity of Daily Life scale (MG-ADL) to rate their level of functional burden. For the DM1-Activ a score of 40 alludes no impairment and a score of 0 indicates the highest functional burden of physical activity. This scale has proven to be practical, reliable and valid. For the MG-ADL the total score ranges from 0 to 24, a score of 0 denotes no and 24 the highest functional burden. It should be noted that this scale is not adjusted for DM1. The rationale was to gain information about muscle fatigue and consequently the neuromuscular junction.

Diagnostic Test: Low frequency repetitive stimulation
Neuromuscular transmission was tested by using short-lasting low frequency RNS (10 stimuli at 3 Hz). The test was applied on the abductor digiti minimi (ADM), anterior tibial, orbiculis oculi, trapezius, anconeus and EDB muscles of one side, in this particular order, by supramaximal stimulation of the corresponding nerve.

Active Comparator: grip strength via dynamometer

The isometric grip strength was tested by using a dynamometer. The subject will be asked to perform an increasing force against the dynamometer over a period of several seconds.

Diagnostic Test: Low frequency repetitive stimulation
Neuromuscular transmission was tested by using short-lasting low frequency RNS (10 stimuli at 3 Hz). The test was applied on the abductor digiti minimi (ADM), anterior tibial, orbiculis oculi, trapezius, anconeus and EDB muscles of one side, in this particular order, by supramaximal stimulation of the corresponding nerve.

Active Comparator: short exercise test

The subject was asked to contract the ADM muscle as hard as possible in isometric conditions for 10 seconds. CMAP's was recorded 2 seconds after the end of the exercise and then every 10 seconds for 50 seconds.

Diagnostic Test: Low frequency repetitive stimulation
Neuromuscular transmission was tested by using short-lasting low frequency RNS (10 stimuli at 3 Hz). The test was applied on the abductor digiti minimi (ADM), anterior tibial, orbiculis oculi, trapezius, anconeus and EDB muscles of one side, in this particular order, by supramaximal stimulation of the corresponding nerve.

Active Comparator: needle EMG

The electrical myotonia of each examined muscle was scored according to the Streiss and Sun scale.

Diagnostic Test: Low frequency repetitive stimulation
Neuromuscular transmission was tested by using short-lasting low frequency RNS (10 stimuli at 3 Hz). The test was applied on the abductor digiti minimi (ADM), anterior tibial, orbiculis oculi, trapezius, anconeus and EDB muscles of one side, in this particular order, by supramaximal stimulation of the corresponding nerve.

Outcome Measures

Primary Outcome Measures

  1. Reproducibility of rapid decrement at low frequency stimulation. [1 year]

    Low stimulation frequency was tested in 6 muscles, to verify the presence of an anomalie of the neuromuscular transmission.

Secondary Outcome Measures

  1. Correlation of decrement with grade of EMG-myotonia [1 year]

    Search of correlation between decrement, obtained bij low frequency stimulation, and EMG-myotonia (via needle EMG), to differentiate muscle fiber hypoexcitability in the context of myotonia, from neuromuscular junction block resulting in decrement of the CMA

  2. Is there any clinical expression (muscle fatigability) of a possible neuromuscular junction dysfunction [1 year]

    Search of correlation between muscle fatique (questionnaires and grip strength via dynamometer) and decrement of CMAP (compound muscle action potential).

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • genetically confirmed DM1
Exclusion Criteria:
  • minor age

  • auto-immune diseases

  • medical conditions involving the neuromuscular junction: (myasthenia gravis, Lambert-Eaton myasthenic syndrome, congenital myasthenia syndromes).

Contacts and Locations

Locations

Site City State Country Postal Code
1 UZ Brussel Jette Brussels Hoofdstedelijk Gewest Belgium 1000

Sponsors and Collaborators

  • Vrije Universiteit Brussel

Investigators

  • Principal Investigator: Jella De Ville, MD, Universitair Ziekenhuis Brussel

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Jella De Ville, medical doctor, principal investigator, Vrije Universiteit Brussel
ClinicalTrials.gov Identifier:
NCT05662150
Other Study ID Numbers:
  • Steinert study
First Posted:
Dec 22, 2022
Last Update Posted:
Dec 22, 2022
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 22, 2022